Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 10/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 6/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498830 | 0.96 | MAP3K5 (0.48) | MAP3K5CSNK1DCSNK1EPIK3CG | |
| Trifluoroacetic Acid SCHEMBL3486132 | 0.87 | MAP3K5 (0.48) | MAP3K5CSNK1DCSNK1EDPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3486927 | 0.85 | CSNK1D (0.51) | MAP3K5CSNK1DCSNK1E | |
| Trifluoroacetic Acid SCHEMBL3486317 | 0.85 | MAP3K5 (0.46) | MAP3K5CSNK1DCSNK1EDPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3485546 | 0.84 | MAP3K5 (0.46) | MAP3K5CSNK1DCSNK1EDPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3485934 | 0.83 | MAP3K5 (0.52) | MAP3K5CSNK1DCSNK1EKDRPIK3CG | |
| SCHEMBL13498833 | 0.81 | MAP3K5 (0.52) | MAP3K5CSNK1DCSNK1E | |
| SCHEMBL13498934 | 0.81 | MAP3K5 (0.52) | MAP3K5CSNK1DCSNK1E | |
| Trifluoroacetic Acid SCHEMBL3486576 | 0.81 | MAP3K5 (0.44) | MAP3K5CSNK1DCSNK1EDPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3485628 | 0.81 | MAP3K5 (0.45) | MAP3K5CSNK1DCSNK1EDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | NOVO NORDISK HEALTHCARE A/G (CH) | 2006-09-07 | — | — | US | disclosed |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | NOVO NORDISK A/S (DK) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198819-A1 | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | GALE, GALNT2, GALNT1 | MAP3K5 3147/4885CSNK1D 3032/4885CSNK1E 2575/4885 |
| US-20060182714-A1 | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides | VIP, PTMS, PDGFA | MAP3K5 2379/4885CSNK1D 3725/4885CSNK1E 2775/4885 |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | MAP3K5 2379/4885CSNK1D 3725/4885CSNK1E 2775/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | MAP3K5 3147/4885CSNK1D 3032/4885CSNK1E 2575/4885 |
| US-20100028939-A1 | Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest | GALE, GALNT2, GALNT1 | MAP3K5 3147/4885CSNK1D 3032/4885CSNK1E 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.